Nicole Mayer-Hamblett.

Frank J. Accurso, M.D http://www.tadacip.net ., Steven M. Rowe, M.D., J.P. Clancy, M.D., Michael P. Boyle, M.D., Jordan M. Dunitz, M.D., Peter R. Durie, M.D., Scott D. Sagel, M.D., Douglas B. Hornick, M.D., Michael W. Konstan, M.D., Scott H. Donaldson, M.D., Richard B. Moss, M.D., Joseph M. Pilewski, M.D., Ronald C. Rubenstein, M.D., Ph.D., Ahmet Z. Uluer, D.O., Moira L. Aitken, M.D., Steven D. Freedman, M.D., Ph.D., Lynn M. Rose, Ph.D., Nicole Mayer-Hamblett, Ph.D., Qunming Dong, Ph.D., Jiuhong Zha, Ph.D., Anne J.

Major exclusion requirements were long-term receipt of systemic anticoagulant therapy, a central venous catheter inserted through guidewire exchange, current use of antibiotics for catheter-related bacteremia, main hemorrhage or intracranial bleeding in the previous 4 weeks, intracranial or intraspinal neoplasm, breast-feeding or pregnancy, and pericarditis. Individuals with known catheter-related bacteremia could be eligible for the study once the infection have been treated and the individual hadn’t received antibiotics for an interval covering three hemodialysis periods. Patients were recruited at 11 Canadian sites, within 2 weeks after insertion of the catheter; during the period before recruitment, the catheters were managed according to the usual practice at each middle .